Skip to main content

Arovella Therapeutics focused on driving ALA-101 into the clinic

Arovella Therapeutics Ltd (ASX:ALA) CEO Michael Baker speaks with Proactive following the company’s successful placement which raised $4.1 million. ALA also aims to raise an extra $1 million via a share purchase plan. The funds will allow the biotechnology company, which is focused on developing its invariant Natural Killer T (iNKT) cell therapy platform, to fund the development of ALA-101 towards clinical trials and to enhance Arovella’s iNKT cell pipeline.

Contact Details

Proactive Investors

Jonathan Jackson

+61 413 713 744

jonathan@proactiveinvestors.com

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.